We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Bempedoic Acid (Nexletol) — ATP-citrate lyase inhibitor
An FDA-approved oral LDL-cholesterol-lowering drug (Nexletol) that inhibits ATP-citrate lyase (ACL) upstream of statins in the cholesterol-synthesis pathway. Because it is a prodrug activated in the liver — not muscle — it largely avoids statin-type muscle pain, making it a key option for statin-intolerant patients. The landmark CLEAR Outcomes RCT (~14,000 patients) showed reduced major cardiovascular events. Lowers LDL-C ~15-25% as monotherapy. Raises uric acid (gout), liver enzymes, and carries a small tendon-rupture signal. Prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Bempedoic Acid is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Bempedoic Acid studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2016–2026 with a typical study size of 238 participants.
Based on 93 studies · 36 meta-analyses · 32 RCTs · 123,439 total participants
Confidence
High confidenceBy outcome
Bempedoic acid has strong, consistent human evidence: a coordinated phase-3 LDL-lowering program (CLEAR Harmony/Wisdom/Serenity/Tranquility) plus the landmark CLEAR Outcomes RCT (~14,000 statin-intolerant patients) showing reduced major adverse cardiovascular events. LDL reductions are moderate (~15-25% monotherapy) rather than statin-level, and it carries gout/uric-acid, liver-enzyme, creatinine, and small tendon-rupture risks — so a strong but not perfect score.
71 rigorous studies
30 randomized trials · 36 meta-analyses · 28 systematic reviews
Our evidence rating for Bempedoic Acid is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
20 trials ongoing or recruiting · 29 completed on ClinicalTrials.gov
17 of the completed trials have posted results
Registered trials show research momentum for Bempedoic Acid, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Bempedoic acid is an FDA-approved oral lipid-lowering drug (Nexletol; co-formulated with ezetimibe as Nexlizet) that inhibits ATP-citrate lyase (ACL), an enzyme that sits upstream of HMG-CoA reductase in the hepatic cholesterol-synthesis pathway.
Inhibiting ACL reduces cholesterol synthesis, which upregulates LDL receptors and clears LDL particles from the blood — the same downstream mechanism statins exploit, but at a different step.
Its defining feature is that it is a prodrug activated by an enzyme (very-long-chain acyl-CoA synthetase-1) that is expressed in the liver but essentially absent from skeletal muscle, so the active drug is not generated in muscle tissue.
This is why bempedoic acid largely avoids the myalgia and muscle complaints that lead many patients to discontinue statins, and it is positioned primarily for statin-intolerant patients or as add-on therapy when statins plus ezetimibe do not reach LDL goals.
As monotherapy it lowers LDL-C roughly 15-25%, with larger reductions when combined with ezetimibe.
The evidence base is genuinely strong for a lipid drug: a coordinated phase-3 program (CLEAR Harmony, CLEAR Wisdom, CLEAR Serenity, CLEAR Tranquility) established consistent LDL-lowering and tolerability, and the landmark CLEAR Outcomes cardiovascular-outcomes trial (~14,000 statin-intolerant patients) demonstrated a significant reduction in major adverse cardiovascular events.
The honest caveats: bempedoic acid raises uric acid and can precipitate gout, modestly raises liver enzymes, can raise creatinine, and carries a small increased risk of tendon rupture; CLEAR Outcomes also saw slightly higher rates of gout and gallstones (cholelithiasis).
It is a real, effective prescription drug with a favorable but not risk-free profile — not a supplement, and not a longevity or off-label optimization compound.
Inhibits ACL, an enzyme upstream of HMG-CoA reductase in hepatic cholesterol synthesis, reducing cholesterol production and upregulating LDL receptors to clear LDL from the blood.
Activated by acyl-CoA synthetase-1, which is present in liver but essentially absent in skeletal muscle — so the active drug is not formed in muscle, largely avoiding statin-type myalgia.
Lower hepatic cholesterol synthesis upregulates LDL receptors, increasing clearance of circulating LDL-C and lowering it ~15-25% as monotherapy.
How Bempedoic Acid works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Use with caution — bempedoic acid raises uric acid and can precipitate flares; monitor and manage.
Counsel on tendon-rupture warning signs and discontinue promptly if they occur.
Observe statin dose limits to avoid myopathy from raised statin levels.
Bempedoic acid raises blood levels of these statins, increasing myopathy risk — dose limits apply.
May add to the small tendon-rupture risk.
Tip: Monitor uric acid; treat gout flares; caution in patients with a gout history.
Tip: Check liver enzymes at baseline and periodically; creatinine rise is usually small and non-progressive.
Tip: Discontinue at the first sign of tendon pain or swelling; higher risk in older adults and with corticosteroids/fluoroquinolones.
Bempedoic Acid has an evidence score of 4.3/10 — emerging evidence based on 71 indexed studies, including 1 meta-analysis. An FDA-approved oral LDL-cholesterol-lowering drug (Nexletol) that inhibits ATP-citrate lyase (ACL) upstream of statins in the cholesterol-synthesis pathway. Because it is a prodrug activated in the liver — not muscle — it largely avoids statin-type muscle pain, making it a key option for statin-intolerant patients. The landmark CLEAR Outcomes RCT (~14,000 patients) showed reduced major cardiovascular events. Lowers LDL-C ~15-25% as monotherapy. Raises uric acid (gout), liver enzymes, and carries a small tendon-rupture signal. Prescription drug, not a supplement. Representative study: PMID 32673317.
The commonly studied dose of Bempedoic Acid is 180 mg orally once daily, with or without food, under a clinician. Available alone (Nexletol) or co-formulated with ezetimibe 10 mg (Nexlizet). A prescription drug — dosing is set by a prescriber.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Bempedoic Acid — consistent daily use matters more than the time of day. Once daily, with or without food; consistency matters more than timing.
Bempedoic Acid is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are hyperuricemia / gout, raised liver enzymes / creatinine, tendon rupture. Use caution if any of these apply to you: Concurrent simvastatin >20 mg or pravastatin >40 mg (bempedoic acid raises their levels); Active gout flare without management; History of tendon rupture related to similar agents.
Pioglitazone (Actos)
Mostly mechanism / observationalAn oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 93 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research